Abstract:Lung cancer is a significant cause of cancer-related death worldwide. It can be broadly categorised into small-cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC). Surgical intervention, radiation therapy, and the administration of chemotherapeutic medications are among the current treatment modalities. However, the application of chemotherapy may be limited in more advanced stages of metastasis due to the potential for adverse effects and a lack of cell selectivity. Although small-molecule anticancer treatments have demonstrated effectiveness, they still face several challenges. The challenges at hand in this context comprise insufficient solubility in water, limited bioavailability at specific sites, adverse effects, and the requirement for epidermal growth factor receptor inhibitors that are genetically tailored. Bio-macromolecular drugs, including small interfering RNA (siRNA) and messenger RNA (mRNA), are susceptible to degradation when exposed to the bodily fluids of humans, which can reduce stability and concentration. In this context, nanoscale delivery technologies are utilised. These agents offer encouraging prospects for the preservation and regulation of pharmaceutical substances, in addition to improving the solubility and stability of medications. Nanocarrier-based systems possess the notable advantage of facilitating accurate and sustained drug release, as opposed to traditional systemic methodologies. The primary focus of scientific investigation has been to augment the therapeutic efficacy of nanoparticles composed of lipids. Numerous nanoscale drug delivery techniques have been implemented to treat various respiratory ailments, such as lung cancer. These technologies have exhibited the potential to mitigate the limitations associated with conventional therapy. As an illustration, applying nanocarriers may enhance the solubility of small-molecule anticancer drugs and prevent the degradation of bio-macromolecular drugs. Furthermore, these devices can administer medications in a controlled and extended fashion, thereby augmenting the therapeutic intervention's effectiveness and reducing adverse reactions. However, despite these promising results, challenges remain that must be addressed. Multiple factors necessitate consideration when contemplating the application of nanoparticles in medical interventions. To begin with, the advancement of more efficient delivery methods is imperative. In addition, a comprehensive investigation into the potential toxicity of nanoparticles is required. Finally, additional research is needed to comprehend these treatments' enduring ramifications. Despite these challenges, the field of nanomedicine demonstrates considerable promise in enhancing the therapy of lung cancer and other respiratory diseases.

Biomembrane-derived nanoplexes for SiRNAs-pioneer innovation in delivery to lung adenocarcinoma

Systemic Delivery Of Therapeutic Sirna By Multifunctional Mesoporous Silica-Based Nanocarrier Inhibits Lung Cancer Growth And Metastasis

Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm

Stimuli-Responsive and Highly Penetrable Nanoparticles As a Multifunctional Nanoplatform for Boosting Nonsmall Cell Lung Cancer Sirna Therapy

Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?

Precision arrows: Navigating breast cancer with nanotechnology siRNA

A Nanoplatform Self-Assembled by Coordination Delivers Sirna for Lung Cancer Therapy

Highly Effective Inhibition of Lung Cancer Growth and Metastasis by Systemic Delivery of Sirna Via Multimodal Mesoporous Silica-Based Nanocarrier.

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Fullerene-based nanocomplex assists pulmonary delivery of siRNA for treating metastatic lung cancer

Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy

Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer Sirna Therapy in Vivo.

Abstract 4529: Self-assembled Lipid-Polymer Hybrid Nanoparticles for the Sustained Delivery of Sirna and the Treatment of Drug-Resistant Cancers.

Efficient nanocarriers of siRNA therapeutics for cancer treatment

Lipid Nanoparticles in Lung Cancer Therapy

Au-siRNA@ Aptamer Nanocages As a High-Efficiency Drug and Gene Delivery System for Targeted Lung Cancer Therapy

Biomacromolecule-mediated Pulmonary Delivery of Sirna and Anti-Sense Oligos: Challenges and Possible Solutions

Selective Cell Penetrating Peptide-Functionalized Envelope-Type Chimeric Lipopepsomes Boost Systemic Rnai Therapy For Lung Tumors

Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer

Aerosol Delivery of Stabilized Polyester-Sirna Nanoparticles to Silence Gene Expression in Orthotopic Lung Tumors.

A Nanoconfined Loading Strategy for Highly Efficient Sirna Delivery and Cancer Therapy